25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

SPRB (Spruce BiosciencesĀ Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Spruce BiosciencesĀ Inc together

I guess you are interested in Spruce BiosciencesĀ Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • šŸ“Š Fundamental Analysis (FA) – Spruce BiosciencesĀ Inc’s Financial Insights
  • šŸ“ˆ Technical Analysis (TA) – Spruce BiosciencesĀ Inc’s Price Targets

I'm going to help you getting a better view of Spruce BiosciencesĀ Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Spruce BiosciencesĀ Inc

I send you an email if I find something interesting about Spruce BiosciencesĀ Inc.

1. Quick Overview

1.1. Quick analysis of Spruce BiosciencesĀ Inc (30 sec.)










1.2. What can you expect buying and holding a share of Spruce BiosciencesĀ Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
13.6%

What is your share worth?

Current worth
$0.35
Expected worth in 1 year
$-0.88
How sure are you?
18.2%

+ What do you gain per year?

Total Gains per Share
$-1.23
Return On Investment
-1,117.2%

For what price can you sell your share?

Current Price per Share
$0.11
Expected price per share
$0.0699 - $0.257
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Spruce BiosciencesĀ Inc (5 min.)




Live pricePrice per Share (EOD)
$0.11
Intrinsic Value Per Share
$-9.38 - $-10.86
Total Value Per Share
$-9.03 - $-10.51

2.2. Growth of Spruce BiosciencesĀ Inc (5 min.)




Is Spruce BiosciencesĀ Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$15.3m$81.2m-$42.5m-109.8%

How much money is Spruce BiosciencesĀ Inc making?

Current yearPrevious yearGrowGrow %
Making money-$13.8m-$11.6m-$2.1m-15.7%
Net Profit Margin-1,851.3%-479.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Spruce BiosciencesĀ Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Spruce BiosciencesĀ Inc?

Welcome investor! Spruce BiosciencesĀ Inc's management wants to use your money to grow the business. In return you get a share of Spruce BiosciencesĀ Inc.

First you should know what it really means to hold a share of Spruce BiosciencesĀ Inc. And how you can make/lose money.

Speculation

The Price per Share of Spruce BiosciencesĀ Inc is $0.11. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Spruce BiosciencesĀ Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Spruce BiosciencesĀ Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.35. Based on the TTM, the Book Value Change Per Share is $-0.31 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Spruce BiosciencesĀ Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.32-290.5%-0.33-295.5%-0.28-251.6%-0.29-260.7%-0.26-232.7%-0.24-219.0%
Usd Book Value Change Per Share-0.33-303.4%-0.31-279.3%-0.24-222.7%-0.15-135.2%0.0545.8%0.0214.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.1%0.000.1%0.015.1%0.014.7%
Usd Total Gains Per Share-0.33-303.4%-0.31-279.3%-0.24-222.5%-0.15-135.1%0.0650.9%0.0219.1%
Usd Price Per Share0.29-0.43-2.03-1.35-4.04-3.67-
Price to Earnings Ratio-0.23--0.40--1.88--1.27--4.68--4.26-
Price-to-Total Gains Ratio-0.87--1.81--8.45--4.79--15.60--15.60-
Price to Book Ratio0.83-0.55-1.04-0.81-1.60-1.45-
Price-to-Total Gains Ratio-0.87--1.81--8.45--4.79--15.60--15.60-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.11
Number of shares9090
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.310.05
Usd Total Gains Per Share-0.310.06
Gains per Quarter (9090 shares)-2,792.65509.00
Gains per Year (9090 shares)-11,170.602,036.00
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-11171-1118120518312026
20-22341-2235241036624062
30-33512-3352361454946098
40-44682-4469481973258134
50-55853-558651024915610170
60-67024-6703612291098712206
70-78194-7820714331281914242
80-89365-8937816381465016278
90-100535-10054918431648118314
100-111706-11172020481831220350

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.022.00.00.0%0.022.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%4.018.00.018.2%4.018.00.018.2%
Dividend per Share0.00.04.00.0%2.00.010.016.7%3.00.017.015.0%3.00.019.013.6%3.00.019.013.6%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%4.018.00.018.2%4.018.00.018.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Spruce BiosciencesĀ Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.334-0.307-8%-0.245-27%-0.149-55%0.050-763%0.016-2206%
Book Value Per Share--0.3490.914-62%1.924-82%1.577-78%1.730-80%1.512-77%
Current Ratio--1.9523.847-49%4.725-59%5.357-64%8.175-76%7.509-74%
Debt To Asset Ratio--0.5160.325+59%0.245+110%0.253+104%0.278+86%0.937-45%
Debt To Equity Ratio--1.0650.543+96%0.325+228%0.366+191%0.271+293%0.247+332%
Dividend Per Share----0%0.000-100%0.000-100%0.006-100%0.005-100%
Enterprise Value--22038428.83541307590.804-47%160964580.168-86%116775858.426-81%278620297.659-92%278620297.659-92%
Eps---0.320-0.325+2%-0.277-13%-0.287-10%-0.256-20%-0.241-25%
Ev To Ebitda Ratio---0.394-1.467+273%-3.533+798%-2.840+622%-7.428+1787%-7.428+1787%
Ev To Sales Ratio--7.90511.936-34%15.916-50%14.936-47%14.936-47%14.936-47%
Free Cash Flow Per Share---0.290-0.315+9%-0.216-25%-0.253-13%-0.227-22%-0.215-26%
Free Cash Flow To Equity Per Share---0.299-0.326+9%-0.225-25%-0.160-46%-0.023-92%0.015-2059%
Gross Profit Margin--1.0001.0000%1.0010%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---10.860----------
Intrinsic Value_10Y_min---9.383----------
Intrinsic Value_1Y_max---1.025----------
Intrinsic Value_1Y_min---1.007----------
Intrinsic Value_3Y_max---3.128----------
Intrinsic Value_3Y_min---2.985----------
Intrinsic Value_5Y_max---5.289----------
Intrinsic Value_5Y_min---4.905----------
Market Cap4645443.000-174%12748428.83518101090.804-30%85791830.168-85%58911025.092-78%185922167.893-93%169020152.630-92%
Net Profit Margin---20.145-18.513-8%-4.799-76%-8.313-59%-4.988-75%-4.535-77%
Operating Margin---20.093-10.007-50%-4.754-76%-5.458-73%-3.275-84%-2.977-85%
Operating Ratio--20.79221.304-2%6.282+231%9.842+111%5.905+252%5.368+287%
Pb Ratio0.315-164%0.8320.551+51%1.043-20%0.812+3%1.599-48%1.454-43%
Pe Ratio-0.086+62%-0.227-0.397+75%-1.881+729%-1.270+459%-4.682+1963%-4.256+1775%
Price Per Share0.110-164%0.2900.426-32%2.031-86%1.354-79%4.042-93%3.675-92%
Price To Free Cash Flow Ratio-0.095+62%-0.250-0.375+50%1.533-116%-0.206-18%-4.242+1594%-3.856+1440%
Price To Total Gains Ratio-0.330+62%-0.869-1.811+108%-8.450+872%-4.790+451%-15.596+1694%-15.596+1694%
Quick Ratio--1.6352.894-44%4.878-66%6.387-74%9.719-83%8.962-82%
Return On Assets---0.444-0.305-31%-0.110-75%-0.175-61%-0.142-68%-0.210-53%
Return On Equity---0.916-0.514-44%-0.146-84%-0.265-71%-0.196-79%-0.178-81%
Total Gains Per Share---0.334-0.307-8%-0.245-27%-0.149-55%0.056-696%0.021-1692%
Usd Book Value--15324000.00038738000.000-60%81268750.000-81%68675500.000-78%77680050.000-80%67833045.455-77%
Usd Book Value Change Per Share---0.334-0.307-8%-0.245-27%-0.149-55%0.050-763%0.016-2206%
Usd Book Value Per Share--0.3490.914-62%1.924-82%1.577-78%1.730-80%1.512-77%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.006-100%0.005-100%
Usd Enterprise Value--22038428.83541307590.804-47%160964580.168-86%116775858.426-81%278620297.659-92%278620297.659-92%
Usd Eps---0.320-0.325+2%-0.277-13%-0.287-10%-0.256-20%-0.241-25%
Usd Free Cash Flow---12727000.000-13433250.000+6%-9112500.000-28%-10987000.000-14%-10063850.000-21%-9551863.636-25%
Usd Free Cash Flow Per Share---0.290-0.315+9%-0.216-25%-0.253-13%-0.227-22%-0.215-26%
Usd Free Cash Flow To Equity Per Share---0.299-0.326+9%-0.225-25%-0.160-46%-0.023-92%0.015-2059%
Usd Market Cap4645443.000-174%12748428.83518101090.804-30%85791830.168-85%58911025.092-78%185922167.893-93%169020152.630-92%
Usd Price Per Share0.110-164%0.2900.426-32%2.031-86%1.354-79%4.042-93%3.675-92%
Usd Profit---14041000.000-13863000.000-1%-11688250.000-17%-12359166.667-12%-11338200.000-19%-10687000.000-24%
Usd Revenue--697000.000901500.000-23%2531750.000-72%1308083.333-47%784850.000-11%713500.000-2%
Usd Total Gains Per Share---0.334-0.307-8%-0.245-27%-0.149-55%0.056-696%0.021-1692%
 EOD+3 -5MRQTTM+11 -27YOY+5 -353Y+4 -365Y+4 -3610Y+5 -35

3.3 Fundamental Score

Let's check the fundamental score of Spruce BiosciencesĀ Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.086
Price to Book Ratio (EOD)Between0-10.315
Net Profit Margin (MRQ)Greater than0-20.145
Operating Margin (MRQ)Greater than0-20.093
Quick Ratio (MRQ)Greater than11.635
Current Ratio (MRQ)Greater than11.952
Debt to Asset Ratio (MRQ)Less than10.516
Debt to Equity Ratio (MRQ)Less than11.065
Return on Equity (MRQ)Greater than0.15-0.916
Return on Assets (MRQ)Greater than0.05-0.444
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Spruce BiosciencesĀ Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.916
Ma 20Greater thanMa 500.080
Ma 50Greater thanMa 1000.072
Ma 100Greater thanMa 2000.166
OpenGreater thanClose0.098
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Spruce BiosciencesĀ Inc

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2025-07-11 14:57:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitĀ Spruce BiosciencesĀ Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareĀ Spruce BiosciencesĀ Inc to theĀ Biotechnology industry mean.
  • A Net Profit Margin of -2,014.5%Ā means thatĀ $-20.14 for each $1Ā in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Spruce BiosciencesĀ Inc:

  • The MRQ is -2,014.5%. The company is making a huge loss. -2
  • The TTM is -1,851.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2,014.5%TTM-1,851.3%-163.2%
TTM-1,851.3%YOY-479.9%-1,371.4%
TTM-1,851.3%5Y-498.8%-1,352.5%
5Y-498.8%10Y-453.5%-45.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,014.5%-88.8%-1,925.7%
TTM-1,851.3%-139.0%-1,712.3%
YOY-479.9%-195.4%-284.5%
3Y-831.3%-247.7%-583.6%
5Y-498.8%-344.1%-154.7%
10Y-453.5%-488.1%+34.6%
4.3.1.2. Return on Assets

Shows howĀ efficientĀ Spruce BiosciencesĀ Inc is using its assets to generate profit.

  • Above 5% is considered healthyĀ but always compareĀ Spruce BiosciencesĀ Inc to theĀ Biotechnology industry mean.
  • -44.4% Return on Assets means thatĀ Spruce BiosciencesĀ Inc generatedĀ $-0.44 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Spruce BiosciencesĀ Inc:

  • The MRQ is -44.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -30.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-44.4%TTM-30.5%-13.9%
TTM-30.5%YOY-11.0%-19.5%
TTM-30.5%5Y-14.2%-16.3%
5Y-14.2%10Y-21.0%+6.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-44.4%-11.4%-33.0%
TTM-30.5%-11.6%-18.9%
YOY-11.0%-11.4%+0.4%
3Y-17.5%-11.7%-5.8%
5Y-14.2%-11.9%-2.3%
10Y-21.0%-13.7%-7.3%
4.3.1.3. Return on Equity

Shows how efficient Spruce BiosciencesĀ Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareĀ Spruce BiosciencesĀ Inc to theĀ Biotechnology industry mean.
  • -91.6% Return on Equity means Spruce BiosciencesĀ Inc generated $-0.92Ā for eachĀ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Spruce BiosciencesĀ Inc:

  • The MRQ is -91.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -51.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-91.6%TTM-51.4%-40.2%
TTM-51.4%YOY-14.6%-36.9%
TTM-51.4%5Y-19.6%-31.8%
5Y-19.6%10Y-17.8%-1.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-91.6%-13.6%-78.0%
TTM-51.4%-15.0%-36.4%
YOY-14.6%-14.4%-0.2%
3Y-26.5%-16.8%-9.7%
5Y-19.6%-17.4%-2.2%
10Y-17.8%-19.5%+1.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Spruce BiosciencesĀ Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresĀ how efficient Spruce BiosciencesĀ Inc is operatingĀ .

  • Measures how much profit Spruce BiosciencesĀ Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareĀ Spruce BiosciencesĀ Inc to theĀ Biotechnology industry mean.
  • An Operating Margin of -2,009.3%Ā means the company generated $-20.09 Ā for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Spruce BiosciencesĀ Inc:

  • The MRQ is -2,009.3%. The company is operating very inefficient. -2
  • The TTM is -1,000.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-2,009.3%TTM-1,000.7%-1,008.6%
TTM-1,000.7%YOY-475.4%-525.4%
TTM-1,000.7%5Y-327.5%-673.3%
5Y-327.5%10Y-297.7%-29.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,009.3%-211.1%-1,798.2%
TTM-1,000.7%-249.7%-751.0%
YOY-475.4%-208.3%-267.1%
3Y-545.8%-216.3%-329.5%
5Y-327.5%-342.8%+15.3%
10Y-297.7%-460.8%+163.1%
4.3.2.2. Operating Ratio

Measures how efficient Spruce BiosciencesĀ Inc is keepingĀ operating costsĀ low.

  • Below 1 is considered healthy (always compare toĀ Biotechnology industry mean).
  • An Operation Ratio of 20.79 means that the operating costs are $20.79 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Spruce BiosciencesĀ Inc:

  • The MRQ is 20.792. The company is inefficient in keeping operating costs low. -1
  • The TTM is 21.304. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ20.792TTM21.304-0.512
TTM21.304YOY6.282+15.022
TTM21.3045Y5.905+15.399
5Y5.90510Y5.368+0.537
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.7922.088+18.704
TTM21.3042.680+18.624
YOY6.2823.076+3.206
3Y9.8423.506+6.336
5Y5.9054.724+1.181
10Y5.3686.353-0.985
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Spruce BiosciencesĀ Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Spruce BiosciencesĀ Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toĀ Biotechnology industry mean).
  • A Current Ratio of 1.95Ā means the company has $1.95 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Spruce BiosciencesĀ Inc:

  • The MRQ is 1.952. The company is able to pay all its short-term debts. +1
  • The TTM is 3.847. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ1.952TTM3.847-1.895
TTM3.847YOY4.725-0.878
TTM3.8475Y8.175-4.328
5Y8.17510Y7.509+0.666
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9523.611-1.659
TTM3.8473.745+0.102
YOY4.7254.104+0.621
3Y5.3574.663+0.694
5Y8.1755.722+2.453
10Y7.5096.141+1.368
4.4.3.2. Quick Ratio

Measures if Spruce BiosciencesĀ Inc is able to pay off Short-term Debt but only usingĀ theĀ most liquid assets.

  • Above 1 is considered healthy butĀ always compareĀ Spruce BiosciencesĀ Inc to theĀ Biotechnology industry mean.
  • A Quick Ratio of 1.64Ā means the company can pay off $1.64 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Spruce BiosciencesĀ Inc:

  • The MRQ is 1.635. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.894. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.635TTM2.894-1.259
TTM2.894YOY4.878-1.984
TTM2.8945Y9.719-6.825
5Y9.71910Y8.962+0.758
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6352.799-1.164
TTM2.8943.079-0.185
YOY4.8783.767+1.111
3Y6.3874.296+2.091
5Y9.7195.702+4.017
10Y8.9626.318+2.644
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Spruce BiosciencesĀ Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Ā of Spruce BiosciencesĀ IncĀ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareĀ Spruce BiosciencesĀ Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.52Ā means that Spruce BiosciencesĀ Inc assets areĀ financed with 51.6% credit (debt) and the remaining percentage (100% - 51.6%)Ā is financed by its owners/shareholders.Ā 

Let's take a look of the Debt to Asset Ratio trends of Spruce BiosciencesĀ Inc:

  • The MRQ is 0.516. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.325. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.516TTM0.325+0.190
TTM0.325YOY0.245+0.080
TTM0.3255Y0.278+0.048
5Y0.27810Y0.937-0.659
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5160.329+0.187
TTM0.3250.353-0.028
YOY0.2450.332-0.087
3Y0.2530.340-0.087
5Y0.2780.346-0.068
10Y0.9370.378+0.559
4.5.4.2. Debt to Equity Ratio

Measures ifĀ Spruce BiosciencesĀ Inc is able toĀ pay off its debts by usingĀ shareholders equity.

  • Below 2 is considered healthy butĀ always compareĀ Spruce BiosciencesĀ Inc to theĀ Biotechnology industry mean.
  • A Debt to Equity ratio of 106.5% means that company has $1.07 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Spruce BiosciencesĀ Inc:

  • The MRQ is 1.065. The company is able to pay all its debts with equity. +1
  • The TTM is 0.543. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.065TTM0.543+0.523
TTM0.543YOY0.325+0.218
TTM0.5435Y0.271+0.272
5Y0.27110Y0.247+0.025
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0650.384+0.681
TTM0.5430.438+0.105
YOY0.3250.414-0.089
3Y0.3660.450-0.084
5Y0.2710.457-0.186
10Y0.2470.512-0.265
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresĀ how much money you payĀ for each share forĀ every $1 in earnings Spruce BiosciencesĀ Inc generates.

  • Above 15 is considered overpriced butĀ always compareĀ Spruce BiosciencesĀ Inc to theĀ Biotechnology industry mean.
  • A PE ratio of -0.23 means the investor is paying $-0.23Ā for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Spruce BiosciencesĀ Inc:

  • The EOD is -0.086. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.227. Based on the earnings, the company is expensive. -2
  • The TTM is -0.397. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.086MRQ-0.227+0.141
MRQ-0.227TTM-0.397+0.170
TTM-0.397YOY-1.881+1.484
TTM-0.3975Y-4.682+4.284
5Y-4.68210Y-4.256-0.426
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.086-2.503+2.417
MRQ-0.227-2.085+1.858
TTM-0.397-2.620+2.223
YOY-1.881-3.738+1.857
3Y-1.270-3.746+2.476
5Y-4.682-6.279+1.597
10Y-4.256-6.975+2.719
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Spruce BiosciencesĀ Inc:

  • The EOD is -0.095. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.250. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.375. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.095MRQ-0.250+0.155
MRQ-0.250TTM-0.375+0.125
TTM-0.375YOY1.533-1.908
TTM-0.3755Y-4.242+3.866
5Y-4.24210Y-3.856-0.386
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.095-3.481+3.386
MRQ-0.250-2.738+2.488
TTM-0.375-3.801+3.426
YOY1.533-4.313+5.846
3Y-0.206-5.099+4.893
5Y-4.242-8.483+4.241
10Y-3.856-9.305+5.449
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofĀ Spruce BiosciencesĀ Inc is to cheap or to expensiveĀ compared to its book value.

  • At or below 1 is considered healthyĀ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.83 means the investor is paying $0.83Ā for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Spruce BiosciencesĀ Inc:

  • The EOD is 0.315. Based on the equity, the company is cheap. +2
  • The MRQ is 0.832. Based on the equity, the company is cheap. +2
  • The TTM is 0.551. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.315MRQ0.832-0.516
MRQ0.832TTM0.551+0.281
TTM0.551YOY1.043-0.492
TTM0.5515Y1.599-1.048
5Y1.59910Y1.454+0.145
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.3152.159-1.844
MRQ0.8321.856-1.024
TTM0.5512.142-1.591
YOY1.0432.441-1.398
3Y0.8122.485-1.673
5Y1.5993.666-2.067
10Y1.4544.337-2.883
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Spruce BiosciencesĀ Inc.

4.8.1. Institutions holding Spruce BiosciencesĀ Inc

Institutions are holding 41.333% of the shares of Spruce BiosciencesĀ Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30RiverVest Venture Management LLC6.95820.3924293628100
2024-12-31The Carlyle Group Inc6.86380.0293289651800
2024-12-31Rock Springs Capital Management LP6.18280.0417260912500
2024-12-31Ikarian Capital, LLC2.36970.0571100000010000000
2024-12-31Vanguard Group Inc1.9996084384400
2024-12-31Sands Capital Ventures, LLC1.69620.0654715817-71190-9.0457
2024-12-31Renaissance Technologies Corp0.96180.0003405900-203800-33.4263
2024-12-31ADAR1 Capital Management LLC0.95670.033940371600
2024-12-31BOOTHBAY FUND MANAGEMENT, LLC0.68440.0032888002888000
2024-12-31Geode Capital Management, LLC0.64880273785118374.5188
2024-12-31BlackRock Inc0.2956012473400
2024-12-31UBS Group AG0.203908604586032661784.6154
2024-12-31Northern Trust Corp0.190308030853817.1817
2024-12-31Lion Point Capital, LP0.17770.16497500000
2024-12-31State Street Corp0.1438060700-3700-5.7453
2024-12-31Susquehanna International Group, LLP0.1398058984589840
2024-12-31Shay Capital LLC0.09030.00243811900
2024-12-31HRT FINANCIAL LLC0.08970.000137838378380
2024-12-31XTX Topco Ltd0.08420.0012355491641585.7897
2024-12-31Bridgeway Capital Management, LLC0.08270.000334900-5100-12.75
Total 30.819820.79213005963+1221497+9.4%

4.9.2. Funds holding Spruce BiosciencesĀ Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Vanguard Total Stock Mkt Idx Inv1.5132063855800
2025-03-31Vanguard Institutional Extnd Mkt Idx Tr0.46730.000119718700
2025-02-28Fidelity Extended Market Index0.35030.0002147806-942-0.6333
2025-02-28Fidelity Series Total Market Index0.086503651000
2024-12-31Bridgeway Ultra-Small Company Market0.08270.008134900-5100-12.75
2025-02-28Fidelity Total Market Index0.074703150300
2025-02-28Spartan Extended Market Index Pool E0.07250.0002305909423.1773
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.04330.00011825800
2025-02-28Spartan Total Market Index Pool E0.034601461000
2025-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.03370.000114213-259-1.7897
2024-12-31Northern Trust Extended Eq Market Idx0.03140.00011327100
2025-03-31NT Ext Equity Mkt Idx Fd - L0.03140.00011327100
2025-02-28Fidelity Nasdaq Composite Index0.029901263500
2025-03-31Vanguard U.S. Eq Idx £ Acc0.01920809900
2025-03-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.00760.00013187250.7906
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.00750.0001316231620
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.00750.0001316231620
2025-03-31State St US Extended Mkt Indx NL Cl C0.00660.0001280000
2024-12-31Northern Trust Wilshire 50000.00280119200
2025-03-31BNYM Mellon SL Market Completion UC10.00280.00011192-4-0.3344
Total 2.90550.00951226106+986+0.1%

5.3. Insider Transactions

Insiders are holding 11.731% of the shares of Spruce BiosciencesĀ Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-20Holdings A/s NovoSELL3599790.73
2024-03-18Holdings A/s NovoSELL8420200.77
2024-03-14Holdings A/s NovoSELL19123160.89
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets31,649
Total Liabilities16,325
Total Stockholder Equity15,324
 As reported
Total Liabilities 16,325
Total Stockholder Equity+ 15,324
Total Assets = 31,649

Assets

Total Assets31,649
Total Current Assets30,576
Long-term Assets1,073
Total Current Assets
Cash And Cash Equivalents 25,615
Other Current Assets 4,961
Total Current Assets  (as reported)30,576
Total Current Assets  (calculated)30,576
+/-0
Long-term Assets
Property Plant Equipment 869
Long-term Assets Other 204
Long-term Assets  (as reported)1,073
Long-term Assets  (calculated)1,073
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities15,666
Long-term Liabilities659
Total Stockholder Equity15,324
Total Current Liabilities
Short-term Debt 1,345
Short Long Term Debt 1,345
Accounts payable 1,879
Other Current Liabilities 10,563
Total Current Liabilities  (as reported)15,666
Total Current Liabilities  (calculated)15,132
+/- 534
Long-term Liabilities
Capital Lease Obligations 950
Long-term Liabilities  (as reported)659
Long-term Liabilities  (calculated)950
+/- 291
Total Stockholder Equity
Common Stock4
Retained Earnings -264,309
Other Stockholders Equity 279,629
Total Stockholder Equity (as reported)15,324
Total Stockholder Equity (calculated)15,324
+/-0
Other
Capital Stock4
Cash and Short Term Investments 25,615
Common Stock Shares Outstanding 43,945
Liabilities and Stockholders Equity 31,649
Net Debt -23,611
Net Invested Capital 16,669
Net Working Capital 14,910
Property Plant and Equipment Gross 869
Short Long Term Debt Total 2,004



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
4,692
0
38,968
78,485
162,883
153,991
143,448
135,087
126,486
114,988
104,515
95,298
85,648
139,114
125,962
112,985
103,946
87,539
75,519
65,102
45,209
31,649
31,64945,20965,10275,51987,539103,946112,985125,962139,11485,64895,298104,515114,988126,486135,087143,448153,991162,88378,48538,96804,692000
   > Total Current Assets 
4,112
0
0
4,652
3,924
38,478
73,600
160,397
151,586
111,369
93,922
91,895
95,096
96,506
93,186
83,608
137,236
124,129
111,138
102,183
85,865
73,912
63,573
44,206
30,576
30,57644,20663,57373,91285,865102,183111,138124,129137,23683,60893,18696,50695,09691,89593,922111,369151,586160,39773,60038,4783,9244,652004,112
       Cash And Cash Equivalents 
-4,112
0
0
3,924
-3,924
36,601
72,158
157,150
148,627
78,278
58,363
42,748
23,343
47,210
21,649
24,487
73,926
97,482
98,801
96,339
81,154
69,683
60,055
38,753
25,615
25,61538,75360,05569,68381,15496,33998,80197,48273,92624,48721,64947,21023,34342,74858,36378,278148,627157,15072,15836,601-3,9243,92400-4,112
       Short-term Investments 
8,224
0
0
0
7,848
0
0
0
0
30,945
33,957
46,221
68,005
46,085
68,751
54,590
44,659
23,041
9,231
0
0
0
0
0
0
0000009,23123,04144,65954,59068,75146,08568,00546,22133,95730,94500007,8480008,224
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,000
0
0
0
0
0
0
0
0
0000000015,0000000000000000000
       Other Current Assets 
0
0
0
728
569
1,877
1,442
3,247
2,959
2,146
1,602
2,926
3,748
3,211
5,572
4,531
3,651
3,606
3,106
5,844
4,711
4,229
3,518
2,276
4,961
4,9612,2763,5184,2294,7115,8443,1063,6063,6514,5315,5723,2113,7482,9261,6022,1462,9593,2471,4421,877569728000
   > Long-term Assets 
-4,112
0
0
40
-3,924
490
4,885
2,486
2,405
32,079
41,165
34,591
19,892
8,009
2,112
2,040
1,878
1,833
1,847
1,763
1,674
1,607
1,529
1,003
1,073
1,0731,0031,5291,6071,6741,7631,8471,8331,8782,0402,1128,00919,89234,59141,16532,0792,4052,4864,885490-3,9244000-4,112
       Property Plant Equipment 
0
0
0
0
0
0
1,869
1,793
1,716
1,638
1,559
1,479
1,397
1,314
1,229
1,400
1,353
1,297
1,240
1,181
1,121
1,060
998
934
869
8699349981,0601,1211,1811,2401,2971,3531,4001,2291,3141,3971,4791,5591,6381,7161,7931,869000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
29,768
38,975
32,459
17,601
5,805
0
0
0
0
0
0
0
0
0
0
0
000000000005,80517,60132,45938,97529,768000000000
       Long-term Assets Other 
-4,112
0
0
40
-3,924
490
3,016
693
473
673
631
653
894
890
667
511
496
502
573
547
518
547
531
69
204
204695315475185475735024965116678908946536316734736933,016490-3,9244000-4,112
> Total Liabilities 
0
0
0
35,329
0
9,622
129,926
13,456
13,268
13,342
15,367
15,115
14,745
15,394
16,823
17,162
31,117
29,401
27,604
27,437
20,915
16,350
13,464
16,388
16,325
16,32516,38813,46416,35020,91527,43727,60429,40131,11717,16216,82315,39414,74515,11515,36713,34213,26813,456129,9269,622035,329000
   > Total Current Liabilities 
0
0
0
4,303
6,335
6,335
10,086
9,763
6,851
6,980
9,061
8,871
8,969
10,102
12,001
12,447
22,995
22,734
24,188
24,465
18,394
14,285
11,858
15,246
15,666
15,66615,24611,85814,28518,39424,46524,18822,73422,99512,44712,00110,1028,9698,8719,0616,9806,8519,76310,0866,3356,3354,303000
       Short-term Debt 
0
0
0
1,252
0
1,263
1,908
2,803
332
341
350
360
775
1,191
1,606
1,761
1,851
1,858
1,866
1,873
1,881
1,889
1,897
0
1,345
1,34501,8971,8891,8811,8731,8661,8581,8511,7611,6061,1917753603503413322,8031,9081,26301,252000
       Short Long Term Debt 
0
0
0
1,252
0
1,263
1,908
2,554
0
0
0
0
405
811
1,216
1,622
1,622
1,622
1,622
1,622
1,622
1,622
1,622
1,622
1,345
1,3451,6221,6221,6221,6221,6221,6221,6221,6221,6221,21681140500002,5541,9081,26301,252000
       Accounts payable 
0
0
0
1,878
2,656
2,656
4,002
3,628
2,566
1,113
2,128
2,823
1,109
1,445
2,181
1,426
3,448
945
3,152
3,332
1,891
682
1,799
1,295
1,879
1,8791,2951,7996821,8913,3323,1529453,4481,4262,1811,4451,1092,8232,1281,1132,5663,6284,0022,6562,6561,878000
       Other Current Liabilities 
0
0
0
1,173
0
2,416
4,176
3,332
3,953
5,526
6,583
5,688
7,085
7,466
8,214
9,260
8,491
11,871
11,372
14,349
11,714
10,416
7,465
0
10,563
10,56307,46510,41611,71414,34911,37211,8718,4919,2608,2147,4667,0855,6886,5835,5263,9533,3324,1762,41601,173000
   > Long-term Liabilities 
0
0
0
31,026
0
3,287
119,840
3,693
6,417
6,362
6,306
6,244
5,776
5,292
4,822
4,715
8,122
6,667
3,416
2,972
2,521
2,065
1,606
1,142
659
6591,1421,6062,0652,5212,9723,4166,6678,1224,7154,8225,2925,7766,2446,3066,3626,4173,693119,8403,287031,026000
       Long term Debt Total 
0
0
0
0
0
0
0
1,922
4,843
4,855
0
0
0
0
0
3,293
2,901
2,507
0
0
0
0
0
0
0
00000002,5072,9013,293000004,8554,8431,9220000000
       Other Liabilities 
0
0
0
0
87
87
95
118
8
29
51
73
95
117
139
161
0
3,013
0
0
0
0
0
0
0
00000003,01301611391179573512981189587870000
       Deferred Long Term Liability 
0
0
0
0
200
200
2,347
0
0
0
0
0
0
0
0
0
3,831
2,811
0
0
0
0
0
0
0
00000002,8113,8310000000002,3472002000000
> Total Stockholder Equity
2,070
0
0
-30,637
-2,824
29,346
-51,441
149,427
140,723
130,106
119,720
111,371
100,243
89,121
78,475
68,486
107,997
96,561
85,381
76,509
66,624
59,169
51,638
28,821
15,324
15,32428,82151,63859,16966,62476,50985,38196,561107,99768,48678,47589,121100,243111,371119,720130,106140,723149,427-51,44129,346-2,824-30,637002,070
   Common Stock
0
0
0
1
1
1
1
2
2
3
3
3
3
3
3
3
4
4
4
4
4
4
4
0
4
4044444443333333221111000
   Retained Earnings -264,309-250,268-226,709-218,038-208,857-197,232-187,282-174,928-162,104-149,313-138,169-126,768-114,895-103,133-93,949-82,502-70,728-60,841-52,503-42,916-42,916-31,302000
   Capital Surplus 
0
0
0
0
0
0
0
210,266
211,449
212,634
0
0
0
0
0
218,354
270,285
271,540
0
0
0
0
0
0
0
0000000271,540270,285218,35400000212,634211,449210,2660000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
0
0
0
-27,813
0
800
1,061
210,266
211,449
212,634
213,682
214,685
215,828
216,731
217,514
218,354
270,285
271,540
272,662
273,737
275,477
277,203
278,343
0
279,629
279,6290278,343277,203275,477273,737272,662271,540270,285218,354217,514216,731215,828214,685213,682212,634211,449210,2661,0618000-27,813000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue4,911
Cost of Revenue-0
Gross Profit4,9114,911
 
Operating Income (+$)
Gross Profit4,911
Operating Expense-61,062
Operating Income-56,151-56,151
 
Operating Expense (+$)
Research Development46,418
Selling General Administrative14,644
Selling And Marketing Expenses0
Operating Expense61,06261,062
 
Net Interest Income (+$)
Interest Income3,422
Interest Expense-307
Other Finance Cost-0
Net Interest Income3,115
 
Pretax Income (+$)
Operating Income-56,151
Net Interest Income3,115
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-53,036-59,266
EBIT - interestExpense = -53,036
-53,036
-52,729
Interest Expense307
Earnings Before Interest and Taxes (EBIT)-52,729-52,729
Earnings Before Interest and Taxes (EBITDA)-52,683
 
After tax Income (+$)
Income Before Tax-53,036
Tax Provision-0
Net Income From Continuing Ops-53,036-53,036
Net Income-53,036
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses61,062
Total Other Income/Expenses Net3,115-3,115
 

Technical Analysis of Spruce BiosciencesĀ Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Spruce BiosciencesĀ Inc. The general trend of Spruce BiosciencesĀ Inc is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Spruce BiosciencesĀ Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Spruce BiosciencesĀ Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportĀ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceĀ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Spruce BiosciencesĀ Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.11 < 0.142 < 0.257.

The bearish price targets are: 0.0902 > 0.0795 > 0.0699.

Know someone who trades $SPRB? Share this with them.šŸ‘‡

Spruce BiosciencesĀ Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theĀ moving averageĀ of the selected period.

  • Moving averages are laggingĀ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Spruce BiosciencesĀ Inc. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Spruce BiosciencesĀ Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theĀ momentumĀ of theĀ selected period based on two moving averages.

  • MACD is aĀ lagging momentumĀ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Spruce BiosciencesĀ Inc. The current macd is 0.00660991.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Spruce BiosciencesĀ Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Spruce BiosciencesĀ Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Spruce BiosciencesĀ Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Spruce BiosciencesĀ Inc Daily Moving Average Convergence/Divergence (MACD) ChartSpruce BiosciencesĀ Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Spruce BiosciencesĀ Inc. The current adx is 32.27.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Spruce BiosciencesĀ Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Spruce BiosciencesĀ Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsĀ the current trend.
  • ShowsĀ potential entry signals.
  • ShowsĀ Ā potential exit signals.
  • Can be used to placeĀ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Spruce BiosciencesĀ Inc. The current sar is 0.07219973.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Spruce BiosciencesĀ Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumĀ indicator, meaning the signals are instant.
  • RangesĀ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Spruce BiosciencesĀ Inc. The current rsi is 70.92. The current phase is Overbought in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bear market: Short-term excessive buying, potential for relief decline. Consider shorting, be cautious of potential pullback. -1
  • Trending up: The RSI is trending up. +1
Spruce BiosciencesĀ Inc Daily Relative Strength Index (RSI) ChartSpruce BiosciencesĀ Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesĀ a certain price to multiple prices ranging over time.

  • LeadingĀ momentumĀ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesĀ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Spruce BiosciencesĀ Inc. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Spruce BiosciencesĀ Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Spruce BiosciencesĀ Inc Daily Stochastic Oscillator ChartSpruce BiosciencesĀ Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Ā the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Spruce BiosciencesĀ Inc. The current cci is 146.58.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Spruce BiosciencesĀ Inc Daily Commodity Channel Index (CCI) ChartSpruce BiosciencesĀ Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Spruce BiosciencesĀ Inc. The current cmo is 52.28.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Spruce BiosciencesĀ Inc Daily Chande Momentum Oscillator (CMO) ChartSpruce BiosciencesĀ Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Ā Shows the current price relative to the highest high over the last 14 days.
Ā 

  • Lagging momentum indicator
  • Ranging between 0 andĀ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Spruce BiosciencesĀ Inc. The current willr is -9.72762646.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Spruce BiosciencesĀ Inc Daily Williams %R ChartSpruce BiosciencesĀ Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldĀ 

Score

Let's take a look at the Bollinger Bands of Spruce BiosciencesĀ Inc.

Spruce BiosciencesĀ Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Spruce BiosciencesĀ Inc. The current atr is 0.01258.

Spruce BiosciencesĀ Inc Daily Average True Range (ATR) ChartSpruce BiosciencesĀ Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Ā Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Spruce BiosciencesĀ Inc. The current obv is -96,389,264.

Spruce BiosciencesĀ Inc Daily On-Balance Volume (OBV) ChartSpruce BiosciencesĀ Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Spruce BiosciencesĀ Inc. The current mfi is 80.31.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Spruce BiosciencesĀ Inc Daily Money Flow Index (MFI) ChartSpruce BiosciencesĀ Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Spruce BiosciencesĀ Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-24MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-14MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-05RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-03STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-14STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-07-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside

6.3. Candlestick Patterns

Spruce BiosciencesĀ Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Spruce BiosciencesĀ Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.916
Ma 20Greater thanMa 500.080
Ma 50Greater thanMa 1000.072
Ma 100Greater thanMa 2000.166
OpenGreater thanClose0.098
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Spruce BiosciencesĀ Inc with someone you think should read this too:
  • Are you bullish or bearish on Spruce BiosciencesĀ Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Spruce BiosciencesĀ Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Spruce BiosciencesĀ Inc

I send you an email if I find something interesting about Spruce BiosciencesĀ Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Spruce BiosciencesĀ Inc.

Receive notifications about Spruce BiosciencesĀ Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.